» Articles » PMID: 19776380

Single Nucleotide Polymorphism of TAG-1 Influences IVIg Responsiveness of Japanese Patients with CIDP

Overview
Journal Neurology
Specialty Neurology
Date 2009 Sep 25
PMID 19776380
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Chronic inflammatory demyelinating polyneuropathy (CIDP) is characterized by immune-mediated peripheral demyelination. Although corticosteroid, IV immunoglobulin (IVIg) and plasma exchange have been established as the most effective therapeutics, subpopulations of patients show little or no response to either of these therapies. In this study, we examined whether particular genetic factors influence the therapeutic responsiveness of patients with CIDP.

Methods: One hundred Japanese patients categorized as responders or nonresponders to IVIg therapy participated in our study. We performed an association analysis with single nucleotide polymorphisms (SNPs) and haplotype studies between the IVIg responders and nonresponders.

Results: Two separate SNPs, corresponding to TAG-1 (transient axonal glycoprotein 1) and CLEC10A (C-type lectin domain family 10, member A), showed strong significant differences between responders and nonresponders. Haplotype analysis of a series of expanded SNPs, from TAG-1 or CLEC10A, showed that only TAG-1 included a significant haplotype within 1 linkage disequilibrium block, which accommodates IVIg responsiveness. Diplotype analysis of TAG-1 also supported this observation.

Conclusions: Transient axonal glycoprotein 1 is a crucial molecule involved in IV immunoglobulin responsiveness in Japanese patients with chronic inflammatory demyelinating polyneuropathy.

Citing Articles

Cytokine Gene Polymorphisms in Patients with Chronic Inflammatory Demyelinating Polyneuropathy.

Bozovic I, Perovic V, Basta I, Peric S, Stevic Z, Popadic D Cells. 2023; 12(16).

PMID: 37626843 PMC: 10453148. DOI: 10.3390/cells12162033.


[Prognostic and monitoring biomarkers in chronic inflammatory demyelinating polyneuropathy].

Llaurado A, Sanchez-Tejerina D, Vidal-Taboada J, Salvado M, Sotoca J, Juntas-Morales R Rev Neurol. 2022; 74(7):232-241.

PMID: 35332927 PMC: 11502160. DOI: 10.33588/rn.7407.2021495.


Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.

Hayashi T, Nukui T, Piao J, Sugimoto T, Anada R, Matsuda N Brain Behav. 2021; 11(5):e02084.

PMID: 33617139 PMC: 8119854. DOI: 10.1002/brb3.2084.


Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy.

Kuitwaard K, van Doorn P, Bengrine T, van Rijs W, Baas F, Nagelkerke S Eur J Neurol. 2021; 28(5):1677-1683.

PMID: 33460483 PMC: 8247870. DOI: 10.1111/ene.14742.


Pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy: Insights into Classification and Therapeutic Strategy.

Koike H, Katsuno M Neurol Ther. 2020; 9(2):213-227.

PMID: 32410146 PMC: 7606443. DOI: 10.1007/s40120-020-00190-8.